| Recruiting | A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who To NCT06628687 | Biogen | — |
| Recruiting | Friedreich Ataxia Nerve Ultrasund NCT07508631 | Centre Hospitalier Universitaire de Nice | — |
| Recruiting | Clinical Course Of Disease In Participants With FA-CM NCT06865482 | Lexeo Therapeutics | — |
| Enrolling By Invitation | The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Followi NCT07072676 | LMU Klinikum | N/A |
| Recruiting | A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With F NCT06953583 | Biogen | Phase 3 |
| Recruiting | A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia NCT06874010 | Design Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia NCT07013292 | Centre Hospitalier Universitaire de Nice | — |
| Withdrawn | Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia NCT06560346 | Friedreich's Ataxia Research Alliance | — |
| Recruiting | Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's Ataxia NCT06692296 | IRCCS Eugenio Medea | N/A |
| Not Yet Recruiting | A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants NCT06772870 | Design Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's NCT06623890 | Biogen | — |
| Terminated | A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia NCT06681766 | Larimar Therapeutics, Inc. | Phase 1 |
| Withdrawn | A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia NCT06483802 | Astellas Gene Therapies | Phase 1 |
| Enrolling By Invitation | Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disor NCT06605612 | LMU Klinikum | — |
| Completed | Respiratory Training in Friedreich's Ataxia NCT06539598 | University of Florida | N/A |
| Completed | Measurement of Frataxin mRNA in Biofluids NCT06496451 | University of Florida | — |
| Recruiting | A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in NCT06054893 | Biogen | Phase 1 |
| Recruiting | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia NCT06447025 | Larimar Therapeutics, Inc. | Phase 2 |
| Recruiting | Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study NCT06016946 | Friedreich's Ataxia Research Alliance | — |
| Recruiting | Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia NCT05874388 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Recruiting | Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia NCT05943002 | German Center for Neurodegenerative Diseases (DZNE) | — |
| Withdrawn | Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia NCT03761511 | RWTH Aachen University | Phase 2 |
| Active Not Recruiting | A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia NCT05515536 | PTC Therapeutics | Phase 3 |
| Completed | A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia NCT05485987 | PTC Therapeutics | Phase 2 |
| Completed | Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia NCT05573698 | Design Therapeutics, Inc. | Phase 1 |
| Completed | A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ata NCT05579691 | Larimar Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia NCT05445323 | Lexeo Therapeutics | Phase 1 / Phase 2 |
| Completed | Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) NCT04921930 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 1 / Phase 2 |
| Completed | Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia NCT05285540 | Design Therapeutics, Inc. | Phase 1 |
| Completed | FRDA Investigator Initiated Study (IIS) With Elamipretide NCT05168774 | Children's Hospital of Philadelphia | Phase 1 / Phase 2 |
| Recruiting | Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia NCT05302271 | Weill Medical College of Cornell University | Phase 1 |
| Completed | Evaluation of the Effects of Calcitriol's in the Neurological Symptoms of Friedreich's Ataxia Patients NCT04801303 | Berta Alemany | Phase 4 |
| Completed | Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers NCT05028764 | Larimar Therapeutics, Inc. | — |
| Completed | NAD+ Precursor Supplementation in Friedreich's Ataxia NCT04817111 | Metro International Biotech, LLC | Phase 2 |
| Completed | Coronary Artery Disease in Patients With Friedreich's Ataxia NCT04649866 | University of Pittsburgh | N/A |
| Active Not Recruiting | A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals with Friedreich Ataxia (TRACK-FA NCT04349514 | Monash University | — |
| Active Not Recruiting | Home Based Tele-exercise for People With Chronic Neurological Impairments NCT04564495 | Burke Medical Research Institute | N/A |
| Completed | A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ata NCT04577352 | PTC Therapeutics | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy of Etravirine in Friedreich Ataxia Patients NCT04273165 | IRCCS Eugenio Medea | Phase 2 |
| Completed | Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia NCT04519567 | Larimar Therapeutics, Inc. | Phase 1 |
| Unknown | Characterization of the Interruptions of the GAA Expansion and Study of Their Influence on the Severity of Fri NCT04346238 | University Hospital, Montpellier | — |
| Completed | A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia NCT04255680 | Larimar Therapeutics, Inc. | — |
| Completed | Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia NCT04176991 | Larimar Therapeutics, Inc. | Phase 1 |
| Completed | Instrumented Data Exchange for Ataxia Study NCT04268147 | University of Chicago | — |
| Completed | Micronised Resveratrol as a Treatment for Friedreich Ataxia NCT03933163 | Murdoch Childrens Research Institute | Phase 2 |
| Completed | A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Femal NCT03917225 | Minoryx Therapeutics, S.L. | Phase 2 |
| Completed | Neurology Measures in FA Children NCT03418740 | Children's Hospital of Philadelphia | — |
| Completed | Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxi NCT03214588 | Neurocrine Biosciences | Phase 2 |
| Completed | TCA Cycle in the Dentate in Friedreich's Ataxia NCT03122925 | University of Minnesota | — |
| Completed | Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia NCT03120013 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | N/A |
| Completed | Open Trail of γIFN for Friedreich Ataxia NCT03888664 | IRCCS Eugenio Medea | Phase 2 |
| Completed | Rosuvastatin (Crestor) in Friedreich Ataxia NCT02705547 | Children's Hospital of Philadelphia | EARLY_Phase 1 |
| Completed | Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension NCT02594917 | University of Pittsburgh | — |
| Completed | Methylprednisolone Treatment of Friedreich Ataxia NCT02424435 | Children's Hospital of Philadelphia | EARLY_Phase 1 |
| Completed | Longitudinal Analysis of Oral Communication in Friedreich's Ataxia NCT04631224 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Completed | A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedrei NCT02255435 | Biogen | Phase 2 |
| Completed | Interferon Gamma-1b in Friedreich Ataxia (FRDA) NCT01965327 | Children's Hospital of Philadelphia | Phase 2 |
| Completed | A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA NCT02035020 | Azienda Policlinico Umberto I | Phase 2 |
| Completed | Efficacy Study of Epoetin Alfa in Friedreich Ataxia NCT01493973 | Federico II University | Phase 2 |
| Completed | Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia NCT01776164 | University of Minnesota | — |
| Completed | An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia NCT01716221 | University of Colorado, Denver | Phase 4 |
| Completed | A Study of Resveratrol as Treatment for Friedreich Ataxia NCT01339884 | Murdoch Childrens Research Institute | Phase 1 / Phase 2 |
| Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168 | Sanford Health | — |
| Completed | Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia NCT00824512 | Ipsen | Phase 2 |
| Completed | Idebenone to Treat Friedreich's Ataxia NCT00229632 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
| Completed | Iron-Chelating Therapy and Friedreich Ataxia NCT00224640 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Completed | Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia NCT00078481 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 |
| Completed | Transitional Life Events in Patients With Friedreich's Ataxia: Implications for Genetic Counseling NCT00056186 | National Human Genome Research Institute (NHGRI) | — |
| Completed | Safety Study of Idebenone to Treat Friedreich's Ataxia NCT00015808 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 |
| Active Not Recruiting | FA Clinical Outcome Measures NCT03090789 | Friedreich's Ataxia Research Alliance | — |